Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis

2016 ◽  
Vol 69 ◽  
pp. 226-235 ◽  
Author(s):  
Bernard Escudier ◽  
Vincent Molinie ◽  
Sergio Bracarda ◽  
Pablo Maroto ◽  
Cezary Szczylik ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Final Analysis ◽  
Phase 2 ◽  
First Line ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase

scholarly journals Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial

2013 ◽  
Vol 14 (12) ◽  
pp. 1233-1242 ◽  
Author(s):  
Brian I Rini ◽  
Bohuslav Melichar ◽  
Takeshi Ueda ◽  
Viktor Grünwald ◽  
Mayer N Fishman ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Dose Titration ◽  
Phase 2 ◽  
First Line ◽  
Double Blind ◽  
Phase 2 Trial

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

2013 ◽  
Vol 14 (13) ◽  
pp. 1287-1294 ◽  
Author(s):  
Thomas E Hutson ◽  
Vladimir Lesovoy ◽  
Salman Al-Shukri ◽  
Viktor P Stus ◽  
Oleg N Lipatov ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
First Line ◽  
Open Label ◽  
Phase 3 ◽  
First Line Therapy ◽  
Line Therapy ◽  
Open Label Phase

scholarly journals A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet ◽  
2021 ◽  
Vol 397 (10275) ◽  
pp. 695-703 ◽  
Author(s):  
Sumanta K Pal ◽  
Catherine Tangen ◽  
Ian M Thompson ◽  
Naomi Balzer-Haas ◽  
Daniel J George ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Papillary Renal Cell Carcinoma ◽  
Phase 2 ◽  
Open Label ◽  
Phase 2 Trial ◽  
Open Label Phase

scholarly journals Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

2016 ◽  
Vol 17 (3) ◽  
pp. 378-388 ◽  
Author(s):  
Andrew J Armstrong ◽  
Susan Halabi ◽  
Tim Eisen ◽  
Samuel Broderick ◽  
Walter M Stadler ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Phase 2 ◽  
Open Label ◽  
Cell Renal Cell Carcinoma ◽  
Phase 2 Trial

scholarly journals An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

2018 ◽  
Vol 24 (2) ◽  
pp. 202-210 ◽  
Author(s):  
Toni K. Choueiri ◽  
M. Dror Michaelson ◽  
Edwin M. Posadas ◽  
Guru P. Sonpavde ◽  
David F. McDermott ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Dose Escalation ◽  
Renal Cell ◽  
Open Label ◽  
Dose Escalation Study ◽  
Phase Ib ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document